Sickle cell disease trials in France

In France 39 Also abroad 204

39 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Where
Marseille, Nantes, Rouen Cedex, Toulouse
Age
18 years and over
People
63 worldwide
Run by
CSL Behring
See details and how to joinNCT07224360 · EU 2025-521154-42-00
Phase 4Enrolling by invitation
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
Where
Bordeau, Créteil, Lyon, Marseille, Paris
Age
18 years and over
People
55 worldwide
Run by
Agios Pharmaceuticals, Inc.
See details and how to joinNCT05777993 · EU 2026-526243-35-00
Phase 3Taking people
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
Where
Bordeaux, Creteil, Lyon Cedex 03, Marseille
Age
12 years and over
People
159 worldwide
Run by
Agios Pharmaceuticals, Inc.
See details and how to joinNCT07656415 · EU 2026-526778-18-00
No phaseTaking people
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Where
Paris
Age
18 years and over
People
550
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT06147414
Phase 3Taking people
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Where
Créteil, Marseille, Paris, Toulouse
Age
10 years to 65 years
People
192 worldwide
Run by
Sanofi
See details and how to joinNCT06975865
Phase 2Taking people
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
Where
Bobigny, Bordeaux, Creteil, Lyon Cedex 03, Nantes, Rouen Cedex
Age
12 years and over
People
70 worldwide
Run by
CSL Behring
See details and how to joinNCT06699849 · EU 2024-513440-29-00
Phase 2Taking people
Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease
Where
Créteil, Jossigny, Le Kremlin-Bicêtre, Lyon, Paris, Saint-Denis
Age
9 months to 11 years
People
50 worldwide
Run by
Theravia
See details and how to joinNCT06578507
No phaseNot yet taking people in France
Comparison of Thrombin Generation, Platelet Activation and Aggregation Profiles in Patients With Sickle Cell Disease Depending on Their SS or SC Genotype (DrepAgreg)
Where
Bobigny
Age
18 years and over
People
60 worldwide
Run by
Centre Hospitalier Universitaire de la Guadeloupe
See details and how to joinNCT07852442
Phase 3Not yet taking people in France
A research study to evaluate how well etavopivat works in children with sickle cell disease
Where
Dijon, Grenoble Cedex 9, Paris
Age
Up to 17 years
People
27 worldwide
Run by
Novo Nordisk A/S
See details and how to join2025-524464-38-00 · EU 2025-524464-38-00
Phase 2Taking people
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
Where
Lyon, Paris, Rouen Cedex
Age
6 months to 18 years
People
95 worldwide
Run by
Forma Therapeutics, Inc.
See details and how to joinNCT06198712 · EU 2024-519881-32-00
Phase 3Taking people
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Where
Creteil, Lyon Cedex 03, Paris
Age
2 years and over
People
480 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT06609226 · EU 2024-510805-27-00
Phase 3Taking people
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Where
Bobigny, Bordeaux, Creteil, Grenoble Cedex 9, Lyon Cedex 03, Paris, Rouen Cedex
Age
12 years and over
People
510 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT06612268 · EU 2023-509175-16-00
Phase 3Taking people
Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease
Where
Bordeaux, Lille, Marseille, Nantes, Orléans, Paris, Poitiers, Rouen, Toulouse, Tours
Age
18 years and over
People
104 worldwide
Run by
Nantes University Hospital
See details and how to joinNCT07274254
Phase 3Taking people
Lidocaine for opioid sparing in vaso-occlusive crisis of Sickle Cell Disease
Where
Bordeaux, Les Abymes, Lille Cedex, Marseille, Nantes, ORLEANS, Paris Cedex 20, Poitiers, Rouen, Talence, Toulouse Cedex 9, Tours
Age
18 years and over
People
104
Run by
Centre Hospitalier Universitaire De Nantes
See details and how to join2024-518437-28-00 · EU 2024-518437-28-00
Phase 2/3Taking people
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
Where
Bobigny Cedex, Lyon, Toulouse Cedex 9
Age
12 years to 64 years
People
389 worldwide
Run by
Pfizer
See details and how to joinNCT05431088 · EU 2023-508766-14-00
Phase 1/2Taking people
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Where
Créteil, Marseille, Paris, Strasbourg
Age
18 years and over
People
224 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06481306 · EU 2023-510283-12-00
No phaseNot yet taking people in France
Standard of Care Comparative Arm of Phase 1/2 Gene Therapy Trial DREPAMIR" in Severe Sickle Cell Disease Patients
Where
Paris
Age
12 years to 35 years
People
30
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT07752043
Phase 2Taking people
Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children with Sickle Cell Disease: a single-group, non-randomised, open-label study (KID-BID)
Where
Cayenne, Creteil Cedex, Le Kremlin-Bicêtre, Meaux, Paris Cedex 15, St Denis Cedex
Age
Up to 17 years
People
50
Run by
Theravia
See details and how to join2024-513750-30-00 · EU 2024-513750-30-00
Phase 3Taking people
Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease
Where
Bobigny Cedex, Colombes Cedex, Creteil, Créteil, Creteil Cedex, Le Kremlin-Bicetre, Lyon Cedex 03, Marseille, Paris, Rouen, Rouen Cedex, Toulouse Cedex 9
Age
2 years and over
People
130
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT06818266 · EU 2023-505109-17-00
No phaseNot yet taking people in France
Epidemiology of Invasive Bacterial Infections in Children With Sickle Cell Disease in France Between 2020 and 2025
Where
Argenteuil, Aulnay-sous-Bois, Bondy, Bordeaux, Boulogne-Billancourt, Bry-sur-Marne, Cergy-Pontoise, Clamart, Corbeil-Essonnes, Créteil, Fontainebleau, Gonesse, Jossigny, Le Kremlin-Bicêtre, Mantes-la-Jolie, Marseille, Meaux, Melun, Montfermeil, Nantes, Neuilly-sur-Seine, Nice, Orsay, Paris, Poissy, Rambouillet, Saint-Denis, Versailles, Villeneuve-Saint-Georges
Age
Up to 17 years
People
350
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT07639008
Phase 4Taking people
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Where
Paris
Age
6 months to 100 years
People
130 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04657822 · EU 2024-510734-41-00
Phase 3Not yet taking people in France
Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease
Where
Amiens Cedex 1, Caen, Montivilliers, Rouen, Saint-Aubin-lès-Elbeuf
Age
18 years and over
People
144
Run by
University Hospital, Rouen
See details and how to joinNCT07498309 · EU 2025-522005-38-00
No phaseTaking people
Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care
Where
Créteil, Le Mans, Nantes, Orléans, Rennes, Tours
Age
18 years and over
People
100
Run by
University Hospital, Tours
See details and how to joinNCT07246265 · EU 2024-511985-34-00
Phase 1/2Taking people
Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.
Where
Paris
Age
12 years to 35 years
People
15
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT07432867
Phase 3Taking people
Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric Emergency Department
Where
Aulnays-Sous-Bois, Bondy, Boulogne-Billancourt, Cayenne, Clamart, Colombes, Corbeil-Essonnes, Créteil, Le Coudray, Le Kremlin-Bicetre, Lille Cedex, Nantes, Saint-Denis
Age
Up to 17 years
People
915
Run by
Assistance Publique Hopitaux De Paris
See details and how to join2023-504847-15-00 · EU 2023-504847-15-00